Corrigendum: Immune clearance of highly pathogenic SIV infection

SG Hansen, M Piatek, AB Ventura, CM Hughes, RM Gilbride, JC Ford, K Oswald, R Shoemaker, Y Li, MS Lewis, AN Gilliam, G Xu, N Whizin, BJ Burwitz, SL Planer, JM Turner, AW Legasse, MK Axthelm, JA Nelson, K FruehJB Sacha, JD Estes, BF Keele, PT Edlefsen, JD Lifson, LJ Picker, Michael Jarvis

Research output: Contribution to journalArticlepeer-review

Abstract

The Acknowledgements section of this Letter should have included the following sentence: “We acknowledge the contribution of M. A. Jarvis to the design, construction and initial in vitro characterization of all the strain 68.1-derived RhCMV vectors used in this study, including both previously published RhCMV/SIV vectors and a previously unpublished vector expressing an Mycobacterium tuberculosis Ag85B–ESAT6 fusion protein, used as a negative control in this study.” S.L.P. and J.M.T. did not reply when asked to approve the wording of this Corrigendum. The HTML version of the paper has been corrected.
Original languageEnglish
Pages (from-to)654-654
Number of pages1
JournalNature
Volume514
Issue number7524
DOIs
Publication statusPublished - 30 Oct 2014

Keywords

  • vaccines
  • live attenuated
  • pathogens

Fingerprint

Dive into the research topics of 'Corrigendum: Immune clearance of highly pathogenic SIV infection'. Together they form a unique fingerprint.

Cite this